SAN DIEGO, June 10, 2020 /PRNewswire/ -- Dermata Therapeutics' lead clinical candidate, DMT310, produced statistically significant results at week 4, 8 and 12 for all its primary and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback